Nasacort and Tobi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nasacort (triamcinolone acetonide) and Tobi (tobramycin). Common drug interactions include arthralgia among females and cough among males.

The phase IV clinical study analyzes what interactions people have when they take Nasacort and Tobi. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Nasacort?

Nasacort has active ingredients of triamcinolone acetonide. It is often used in allergies. eHealthMe is studying from 13,298 Nasacort users. Check the latest studies of Nasacort.

What is Tobi?

Tobi has active ingredients of tobramycin. eHealthMe is studying from 10,011 Tobi users. Check the latest studies of Tobi.

On Jul, 25, 2026

14 people who take Nasacort and Tobi together, and have interactions are studied.

What are the common drug interactions of Nasacort and Tobi, by gender? *:

female:

Arthralgia (joint pain)
Back pain
Blood creatine phosphokinase increased
Cough
Dyspnoea (difficult or laboured respiration)
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Headache (pain in head)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Nausea (feeling of having an urge to vomit)

male:

Cough
Pyrexia (fever)
Gastroenteritis clostridial (inflammation of stomach and intestine clostridial)
Haemorrhagic anaemia (anaemia due to excessive bleeding)
Immunodeficiency
Joint swelling
Lymphadenopathy (disease or enlargement of lymph nodes)
Malaise (a feeling of general discomfort or uneasiness)
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)

What are the common drug interactions of Nasacort and Tobi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Upper respiratory tract infection
Chest discomfort
Cough
Cystic fibrosis (disease of the secretary glands)
Influenza
Obstructive airways disorder (a progressive disease that makes it hard to breathe)
Pyrexia (fever)
Secretion discharge
Tracheobronchitis viral (a inflammation or infection, which affects the trachea and bronchi of respiratory tract by viral infection)

20-29:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Influenza
Nausea (feeling of having an urge to vomit)

30-39:

n/a

40-49:

Arthralgia (joint pain)
Back pain
Blood creatine phosphokinase increased
Cough
Dyspnoea (difficult or laboured respiration)
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Headache (pain in head)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Nausea (feeling of having an urge to vomit)

50-59:

n/a

60+:

Asthenia (weakness)
Blood pressure decreased
Haemorrhagic anaemia (anaemia due to excessive bleeding)
Immunodeficiency
Joint swelling
Lymphadenopathy (disease or enlargement of lymph nodes)
Malaise (a feeling of general discomfort or uneasiness)
Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Obstructive airways disorder (a progressive disease that makes it hard to breathe)

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 13 people, 92.86%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 3 people, 21.43%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 3 people, 21.43%
Constipation: 2 people, 14.29%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 7.14%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.14%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 1 person, 7.14%
Cough: 1 person, 7.14%
Depression: 1 person, 7.14%
Dyspnea (difficult or laboured breathing): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Nasacort and Tobi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously